page banner


CorePanel NGS Assays

HapOnco® CorePanel NGS Assays


Product Overview

HapOnco® CorePanel™ NGS Assays detect the entire protein-coding region of 136 critical genes related to lung, gastrointestinal, hepatobiliary and pancreatic, urological, gynecologic and breast cancers, including all NCCN/CSCO guidelines-recommended targetable genes such as EGFR, ALK and ROS1, 12 common cancer-causing fusion genes, 18 IO therapy-related genes and 51 hereditary risk-related genes for evaluating hereditary cancers and syndromes. In addition, HapOnco® CorePanel™ also includes 317 SNP loci associated with chemotherapy responses and side effects. HapOnco® CorePanel™ can guide therapy selection and provide molecular subtyping, prognostic information, as well as hereditary cancer risk assessment to identify high-risk individuals and families who may benefit from preventive intervention.


Product Advantages

(1) Focus on the core testing scope: Emphasize targeted therapy and assess the efficacy of diverse tumor drugs.
(2) Advanced sequencing analysis technology: Ensure effective detection of low-frequency mutations and minimize false negatives.


Applicable Cancer Types

Lung Cancer Lung Cancer
Gastrointestinal Cancer Gastrointestinal Cancer
Hepatobiliary and Pancreatic Cancer Hepatobiliary and Pancreatic Cancer
Breast Cancer Breast Cancer
Gynecologic Cancer Gynecologic Cancer
Urological Cancer Urological Cancer

Applicable Population

Patients with the above-mentioned cancer types who are considering molecular profiling, targeted therapy, immunotherapy and chemotherapy.